PL1809742T3 - Sposoby leczenia stawów związanych z gromadzeniem nadmiaru macierzy pozakomórkowej - Google Patents

Sposoby leczenia stawów związanych z gromadzeniem nadmiaru macierzy pozakomórkowej

Info

Publication number
PL1809742T3
PL1809742T3 PL05812977T PL05812977T PL1809742T3 PL 1809742 T3 PL1809742 T3 PL 1809742T3 PL 05812977 T PL05812977 T PL 05812977T PL 05812977 T PL05812977 T PL 05812977T PL 1809742 T3 PL1809742 T3 PL 1809742T3
Authority
PL
Poland
Prior art keywords
accumulation
methods
extracellular matrix
conditions associated
treating conditions
Prior art date
Application number
PL05812977T
Other languages
English (en)
Inventor
Nancy A Noble
Wayne A Border
Original Assignee
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found filed Critical Univ Utah Res Found
Publication of PL1809742T3 publication Critical patent/PL1809742T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/488Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49Urokinase; Tissue plasminogen activator
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/556Angiotensin converting enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL05812977T 2004-09-27 2005-09-27 Sposoby leczenia stawów związanych z gromadzeniem nadmiaru macierzy pozakomórkowej PL1809742T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/952,361 US7763580B2 (en) 1999-01-05 2004-09-27 Methods for treating conditions associated with the accumulation of excess extracellular matrix
PCT/US2005/034787 WO2006037029A2 (en) 2004-09-27 2005-09-27 Methods for treating conditions associated with the accumulation of excess extracellular matrix
EP05812977.6A EP1809742B1 (en) 2004-09-27 2005-09-27 Methods for treating conditions associated with the accumulation of excess extracellular matrix

Publications (1)

Publication Number Publication Date
PL1809742T3 true PL1809742T3 (pl) 2016-01-29

Family

ID=36119564

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05812977T PL1809742T3 (pl) 2004-09-27 2005-09-27 Sposoby leczenia stawów związanych z gromadzeniem nadmiaru macierzy pozakomórkowej

Country Status (7)

Country Link
US (2) US7763580B2 (pl)
EP (1) EP1809742B1 (pl)
AU (1) AU2005289518A1 (pl)
CA (1) CA2581980A1 (pl)
ES (1) ES2548725T3 (pl)
PL (1) PL1809742T3 (pl)
WO (1) WO2006037029A2 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6918226B2 (en) * 2003-07-03 2005-07-19 Rebecca A. Heilman Automatic utensil wrapping machine
JP5070200B2 (ja) * 2005-04-22 2012-11-07 イーライ リリー アンド カンパニー Tgfベータ1に特異的な抗体
JP6199558B2 (ja) 2009-12-23 2017-09-20 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド イヌにおける腎障害を診断し、そして治療するための組成物および方法
ES2715177T3 (es) * 2010-09-01 2019-06-03 Genzyme Corp Tratamiento de infarto de miocardio usando antagonistas de tgf-beta
ES2590263T3 (es) 2011-02-24 2016-11-21 Hill's Pet Nutrition, Inc. Composiciones y métodos para el diagnóstico de trastornos renales en un felino
WO2012167261A2 (en) 2011-06-03 2012-12-06 Yale University Compositions and methods for treating and preventing neointimal stenosis
EP2917336B1 (en) 2012-11-09 2018-06-27 Marco Archetti Diffusible factors and cancer cells
KR102258457B1 (ko) 2013-03-11 2021-05-31 젠자임 코포레이션 조작된 항-tgf-베타 항체 및 항원-결합 단편
WO2017100782A1 (en) 2015-12-11 2017-06-15 Research Institute At Nationwide Children's Hospital Systems and methods for optimized patent specific tissue engineering vascular grafts
CN110191718A (zh) 2016-12-15 2019-08-30 泰伦基国际有限公司 一种预防和治疗组织器官纤维化的方法
US11938172B2 (en) 2017-06-19 2024-03-26 Talengen International Limited Method for regulating and controlling GLP-1/GLP-1R and drug
WO2019133950A1 (en) * 2017-12-30 2019-07-04 The Regents Of The University Of Colorado, A Body Corporate Smad7 for treatment and prevention of posterior capsule opacification

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
DK0494264T3 (da) 1989-09-29 1998-01-26 Jolla Cancer Res Found Inhibering af transformede vækstfaktor til hindring af akkumulation af ekstracellulær matrix
EP1230929A1 (en) 1991-11-14 2002-08-14 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
WO1993010808A1 (en) 1991-12-04 1993-06-10 La Jolla Cancer Research Foundation INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
WO1997039028A1 (en) 1996-04-12 1997-10-23 American National Red Cross Mutant plasminogen activator-inhibitor type 1 (pai-1) and uses thereof
AU1826799A (en) 1998-01-09 1999-07-26 University Of Utah, The Methods for preventing and treating fibrotic diseases resulting from accumulation of excess extracellular matrix induced by tgfbeta using renin inhibitors
AU771635B2 (en) 1999-01-05 2004-04-01 American National Red Cross, The Methods for treating conditions associated with the accumulation of excess extracellular matrix
EP1620128A1 (en) 2003-04-30 2006-02-01 Genzyme Corporation Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency

Also Published As

Publication number Publication date
ES2548725T3 (es) 2015-10-20
EP1809742B1 (en) 2015-07-15
AU2005289518A1 (en) 2006-04-06
US7763580B2 (en) 2010-07-27
EP1809742A2 (en) 2007-07-25
WO2006037029A3 (en) 2006-07-27
US20080175848A1 (en) 2008-07-24
US20050124534A1 (en) 2005-06-09
EP1809742A4 (en) 2008-03-05
CA2581980A1 (en) 2006-04-06
WO2006037029A2 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
PL1809742T3 (pl) Sposoby leczenia stawów związanych z gromadzeniem nadmiaru macierzy pozakomórkowej
IL186895A0 (en) Methods for treating eye conditions
TWI366828B (en) Wear leveling method and controller using the same
GB0526291D0 (en) Therapeutic method
IL198304A0 (en) Methods for securing strand ends and the resulting devices
EP2105001A4 (en) ENTERPRISE MOBILITY
HU0500170D0 (en) New compounds with therapeutic effects
EP2083857A4 (en) METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
EP1912698A4 (en) OPHTHALMIC INJECTOR SYSTEM
EP2041368A4 (en) FRAME OF BLOCK OF VEGETATION AND BLOCK OF VEGETATION
GB2414542B (en) Backlight unit
TWI348163B (en) Wear leveling method and controller using the same
IL176829A0 (en) Composition for treating pathology associated with msrv/herv-w
HK1118286A1 (en) Dipyrazoles as central nervous system agents
EP1883405A4 (en) METHODS OF TREATING NEPHROLITHIASIS
IL189244A0 (en) Tumescent skin spacing method
GB0706476D0 (en) Spectacle improvement 4
GB0513872D0 (en) Electro-optical subassembly
GB0408345D0 (en) Bath n easy
PL381051A1 (pl) Sposób stymulacji dojrzewania loszek
GB0715201D0 (en) Flavonoids-rich tissues from neomarica gracilis and methods for culturing the same
GB0817436D0 (en) The new scaffolder's level
GB0501925D0 (en) Bath up
GB0506977D0 (en) Bath
GB0513373D0 (en) Bath